Researchers from the MUHC have found that elderly patients with chronic obstructive pulmonary disease (COPD) and asthma who take medication to prevent their attacks face an increased risk of developing cataracts. Their findings, which looked at a large group of Quebecers, are released today in the June issue of the European Respiratory Journal.
"We found that people over the age of 65 who take a cortisone-like medication called inhaled corticosteroids (ICS) to lower their risk of asthma or COPD attacks are actually raising their risk of developing cataracts," says MUHC epidemiologist Dr. Samy Suissa and senior author of the study. "This important information to physicians and patients will help in the management of patients using these drugs"
The researchers looked at 14 years of diagnostic and prescription information from a provincial health database, studying more than 100,000 patients with asthma or COPD with the average age of 78, over 10,000 of whom were subsequently diagnosed with severe cataracts.
The team found a 24 percent increase in the risk of developing a severe cataract for those subjects taking a typical daily dose of ICS. Even at half the daily dose, the researchers found a small increase in the risk of cataracts, a condition that clouds or darkens the lens of the eye and, when left untreated, can permanently blur vision.
The findings lead the researchers to put forth a word of warning: "We recommend that elderly asthma sufferers keep using these very effective medications, but make efforts to reduce the dose of ICS as much as possible," said Dr. Suissa, who is also a professor in McGill Universitys Department of Epidemiology and Biostatistics. He suggests that if seniors do have to take ICS, they use the medication in combination with other drugs that open up the bronchial tubes such as long-acting bronchodilators or anti-leukotrienes. For patients with COPD, however, the message is clear: given the limited efficacy of ICS in COPD, we recommend avoiding their use altogether.
The study was funded by the Fonds de la Recherche en Santé du Québec. Samy Suissa is the recipient of a Distinguished Investigator award from the Canadian Institutes of Health Research.
The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, a university health centre affiliated with the Faculty of Medicine at McGill University. The institute supports over 500 researchers, nearly 1,000 graduate and postdoctoral students, and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge. For further details visit the Research Institute website.
The McGill University Health Centre (MUHC) is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research and teaching. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University--the Montreal Childrens, Montreal General, Royal Victoria, and Montreal Neurological Hospitals, as well as the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field, and to contribute to the development of new knowledge.
Ian Popple | MUHC
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy